Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center - Monroeville
mi
from
Monroeville, PA
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center - Monroeville
mi
from
Monroeville, PA
Click here to add this to my saved trials
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated:  12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated: 12/31/1969
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute, Investigational Drug Service, William M. Cooper Pavilion
mi
from
Pittsburgh, PA
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute, Investigational Drug Service, William M. Cooper Pavilion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center
mi
from
Pittsburgh, PA
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Accountability for Cancer Care Through Undoing Racism and Equity
Accountability for Cancer Care Through Undoing Racism and Equity
Status: Enrolling
Updated:  12/31/1969
Cone Health, Regional Cancer Center
mi
from
Greensboro, NC
Accountability for Cancer Care Through Undoing Racism and Equity
Accountability for Cancer Care Through Undoing Racism and Equity
Status: Enrolling
Updated: 12/31/1969
Cone Health, Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Accountability for Cancer Care Through Undoing Racism and Equity
Accountability for Cancer Care Through Undoing Racism and Equity
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center, Hillman Comprehensive Cancer Center
mi
from
Pittsburgh, PA
Accountability for Cancer Care Through Undoing Racism and Equity
Accountability for Cancer Care Through Undoing Racism and Equity
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center, Hillman Comprehensive Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated:  12/31/1969
David Grant Medical Center
mi
from
Fairfield, CA
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated: 12/31/1969
David Grant Medical Center
mi
from
Fairfield, CA
Click here to add this to my saved trials
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated:  12/31/1969
Essentia Institute of Rural Health
mi
from
Duluth, MN
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated: 12/31/1969
Essentia Institute of Rural Health
mi
from
Duluth, MN
Click here to add this to my saved trials
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated:  12/31/1969
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated: 12/31/1969
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Family Health History in Diverse Care Settings
Family Health History in Diverse Care Settings
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation
mi
from
Sunnyvale, CA
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Solid Tumor Oncology Practice
mi
from
New York, NY
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Solid Tumor Oncology Practice
mi
from
New York, NY
Click here to add this to my saved trials
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
UCLA Ronald Reagan Medical Center
mi
from
Los Angeles, CA
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
UCLA Ronald Reagan Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Centers of America - Southeastern Regional Medical Center
mi
from
Newnan, GA
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Centers of America - Southeastern Regional Medical Center
mi
from
Newnan, GA
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital-Cornell Medical Center
mi
from
New York, NY
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital-Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
State Univ of New York at Stony Brook
mi
from
Stony Brook, NY
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
State Univ of New York at Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Inova Alexandria Hospital CVIR
mi
from
Alexandria, VA
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Inova Alexandria Hospital CVIR
mi
from
Alexandria, VA
Click here to add this to my saved trials
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated:  12/31/1969
Institut Bergonié
mi
from
Bordeaux,
Study of Cryoablation for Metastatic Lung Tumors
Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation
Status: Enrolling
Updated: 12/31/1969
Institut Bergonié
mi
from
Bordeaux,
Click here to add this to my saved trials
GSK1120212+GSK2141795 for Cervical Cancer
A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
GSK1120212+GSK2141795 for Cervical Cancer
A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation
Evaluation of Immunologic Responses in HPV-Associated Oropharyngeal Carcinoma Patients Receiving Chemoradiation Therapy
Status: Enrolling
Updated:  12/31/1969
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation
Evaluation of Immunologic Responses in HPV-Associated Oropharyngeal Carcinoma Patients Receiving Chemoradiation Therapy
Status: Enrolling
Updated: 12/31/1969
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Early Changes In Multiparametric MRI In Prostate Cancer
Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Birmingham VA Medical Center, Birmingham, AL
mi
from
Birmingham, AL
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated:  12/31/1969
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Status: Enrolling
Updated: 12/31/1969
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated:  12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated: 12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated:  12/31/1969
Watson Cancer Center
mi
from
Lakeland, FL
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated: 12/31/1969
Watson Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
UC Davis Cancer Center
mi
from
Sacramento, CA
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
UC Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Cutaneous Oncology and Melanoma Center
mi
from
San Francisco, CA
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Cutaneous Oncology and Melanoma Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of California Los Angeles
mi
from
Santa Monica, CA
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of California Los Angeles
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers, LLP [Denver-Midtown]
mi
from
Denver, CO
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers, LLP [Denver-Midtown]
mi
from
Denver, CO
Click here to add this to my saved trials